4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC lifted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 652.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 110,041 shares of the company’s stock after buying an additional 95,422 shares during the period. Squarepoint Ops LLC’s holdings in 4D Molecular Therapeutics were worth $2,310,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its position in 4D Molecular Therapeutics by 702.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after acquiring an additional 3,026 shares during the period. Quest Partners LLC grew its holdings in shares of 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after purchasing an additional 5,745 shares during the period. Entropy Technologies LP acquired a new stake in shares of 4D Molecular Therapeutics during the 1st quarter worth about $239,000. China Universal Asset Management Co. Ltd. raised its holdings in 4D Molecular Therapeutics by 93.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,579 shares of the company’s stock valued at $305,000 after buying an additional 4,628 shares during the period. Finally, ProShare Advisors LLC acquired a new position in 4D Molecular Therapeutics in the first quarter valued at about $344,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Up 0.7 %

NASDAQ:FDMT opened at $10.34 on Friday. 4D Molecular Therapeutics, Inc. has a 12-month low of $9.44 and a 12-month high of $36.25. The firm has a market cap of $534.61 million, a PE ratio of -4.24 and a beta of 2.77. The stock has a fifty day moving average price of $14.62 and a 200 day moving average price of $21.45.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.09. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $1.90 million. Equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.75 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 22nd. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. BMO Capital Markets decreased their price target on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, July 18th. Leerink Partners reaffirmed an “outperform” rating and issued a $36.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Finally, Chardan Capital boosted their price objective on 4D Molecular Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.25.

Insider Buying and Selling

In other 4D Molecular Therapeutics news, CEO David Kirn sold 12,923 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $22.49, for a total value of $290,638.27. Following the sale, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at approximately $23,820,350.97. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Scott Bizily sold 1,750 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $27.11, for a total transaction of $47,442.50. Following the completion of the sale, the insider now owns 6,781 shares in the company, valued at $183,832.91. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO David Kirn sold 12,923 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $22.49, for a total transaction of $290,638.27. Following the completion of the transaction, the chief executive officer now owns 1,059,153 shares in the company, valued at $23,820,350.97. The disclosure for this sale can be found here. Insiders sold 17,169 shares of company stock worth $396,146 over the last 90 days. 7.30% of the stock is owned by insiders.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.